IA
BLPH

IFP Advisors’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

IFP Advisors’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-67
Closed -$3K – 4162
2018
Q1 		$3K Hold
67
– – ﹤0.01% 3445
2017
Q4 		$3K Buy
+67
New +$1.76K ﹤0.01% 3496

Other funds holding BLPH

NMVA
New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return
PCM
Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

IFP Advisors's BLPH Position: Q2 2018 in Review

IFP Advisors sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q2 2018, closing a stake of 67 shares — an estimated $3K sold.

IFP Advisors first reported a position in BLPH in Q4 2017 and held it in 2 quarters. The position peaked at $3K in Q1 2018. 29 funds tracked by Wall St. Rank hold BLPH as of Q2 2018.

  • IFP Advisors reported no remaining Bellerophon Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
  • IFP Advisors sold 67 Bellerophon Therapeutics, Inc. shares in Q2 2018, an estimated $3K.
  • IFP Advisors first reported a position in Bellerophon Therapeutics, Inc. in Q4 2017 and held it in 2 quarters.
  • IFP Advisors's Bellerophon Therapeutics, Inc. position peaked at $3K in Q1 2018.
  • 29 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q2 2018.

Based on IFP Advisors's 13F filing for Q2 2018, filed 7 Aug 2018.